Christian Marsolais
![Christian Marsolais Christian Marsolais](https://next-gen-conjugates.com/wp-content/uploads/sites/669/2023/10/Christian-Marsolais-Thera-Technologies-150x150.jpg)
Company: Theratechnologies Inc.
Job title: Senior Vice President & Chief Medical Officer
Seminars:
Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization and Improved Tumor Penetration Within Minutes 9:00 am
Understand the rationale for targeting the SORT1 receptor in cancer Discuss the preclinical as well as the emerging clinical data of sudocetaxel zendusortide (TH1902), the lead PDC from Theratechnologies’ SORT1+ Technology™ platform Discuss the unique multimodal MOA of this PDC Explore the potential of SORT1+ Technology™ for future developments, such as novel PDC’s and combinationsRead more
day: Conference Day One AM